Clinical Parkinsonism Related Disorders最新文献

{"title":"A 3-month music-based recreation program added to stable speech-language therapy in institutionalized patients with Parkinson's disease: a feasibility study","authors":"Yasufumi Oi,&nbsp;Haruna Aoki,&nbsp;Tomoyuki Hatsuse,&nbsp;Seira Taniguchi,&nbsp;Seiji Ueno,&nbsp;Akiyoshi Yamamoto,&nbsp;Kensuke Ikenaka","doi":"10.1016/j.prdoa.2026.100485","DOIUrl":"10.1016/j.prdoa.2026.100485","url":null,"abstract":"<div><div>Dysphonia and dysphagia are highly prevalent in late-stage Parkinson's disease (PD), particularly among patients residing in long-term care facilities, yet evidence for rehabilitation interventions in this population remains extremely limited. With increasing longevity, more patients progress to advanced stages marked by frailty, long disease duration, and treatment-resistant symptoms, making the development of effective therapeutic strategies an urgent clinical priority. Here, we conducted an uncontrolled, single-arm, open-label exploratory pre–post feasibility study to evaluate a 12-session group music recreation program added to stable ongoing speech-language therapy in institutionalized patients with Parkinson's disease. Twenty-five of 32 enrolled patients attended at least three of the 12 scheduled sessions and completed pre- and post-program assessments. Outcomes included Maximum Phonation Time (MPT), mean sound pressure, Vocal Handicap Index (VHI), modified water swallowing test (MWST), repetitive saliva swallowing test, Dysphagia Severity Scale, swallowing visual analog scale, and a dysphagia screening questionnaire. In unadjusted Wilcoxon signed-rank analyses, nominal pre–post changes were observed in MPT and MWST, and VHI showed a non-significant trend toward reduction; however, no outcome remained statistically significant after Bonferroni correction. Other swallowing measures and subjective swallowing outcomes did not show clear improvement. These findings suggest that adding group music recreation to stable speech-language therapy is feasible in institutionalized patients with PD and may provide hypothesis-generating signals for selected voice and structured water-swallowing outcomes; controlled studies are needed to determine efficacy.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100485"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148737401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric assessment of a modified part I of the unified multiple system atrophy rating scale","authors":"Anna-Karin Berger,&nbsp;Andreas Rieckmann,&nbsp;Krishan Nighah,&nbsp;Stefano Zanigni","doi":"10.1016/j.prdoa.2026.100510","DOIUrl":"10.1016/j.prdoa.2026.100510","url":null,"abstract":"<div><h3>Background</h3><div>Despite widespread use in MSA clinical trials, the UMSARS has recognized limitations in responsiveness.</div></div><div><h3>Objectives</h3><div>To evaluate the psychometric properties of a modified UMSARS Part I incorporating collapsed response categories (0 and 1) and excluding item 11 (sexual function).</div></div><div><h3>Methods</h3><div>Psychometric properties and responsiveness of the modified UMSARS Part I were assessed and compared with other UMSARS scores using data from a randomized, double-blind, placebo-controlled trial.</div></div><div><h3>Results</h3><div>For the mUMSARS Part I, internal consistency (Cronbach's alpha) was 0.80 at Week 48 and 0.76 at end-of-treatment, and test-retest reliability (intraclass correlation coefficient) was 0.61. Construct validity for mUMSARS Part I ranged from <em>r</em> = 0.51–0.72, comparable to the UMSARS Total score (<em>r</em> = 0.49–0.69) and higher than UMSARS Part I (<em>r</em> = 0.42–0.60). At Week 48, mUMSARS Part I effect sizes across global impression anchors were large in worsening groups (1.64–2.92) and lower in no-change groups (0.97–1.62).</div></div><div><h3>Conclusions</h3><div>The modified scale demonstrates acceptable psychometric properties, supporting its use in trials assessing progression of MSA. Both the original UMSARS Part I and mUMSARS Part I performed well across psychometric assessments; however, the mUMSARS Part I showed consistently stronger construct validity and greater responsiveness to change.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100510"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149199254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between self-reported physical activity levels and patient reported cognitive problems in Parkinson's disease","authors":"Amy W. Amara,&nbsp;Jennifer L. Purks,&nbsp;Connie Marras,&nbsp;Abhishek Hosamath,&nbsp;Karen E. Anderson,&nbsp;Lana M. Chahine,&nbsp;Shirley Eberly,&nbsp;Daniel Kinel,&nbsp;Sneha Mantri,&nbsp;Soania Mathur,&nbsp;David Oakes,&nbsp;David G. Standaert,&nbsp;Daniel Weintraub,&nbsp;Ira Shoulson,&nbsp;Lakshmi Arbatti","doi":"10.1016/j.prdoa.2026.100504","DOIUrl":"10.1016/j.prdoa.2026.100504","url":null,"abstract":"<div><h3>Background</h3><div>Cognitive dysfunction is a highly impactful symptom experienced by some people with Parkinson's disease (PD). Physical activity may slow cognitive impairment in PD.</div></div><div><h3>Objective</h3><div>Evaluate associations between self-reported physical activity and prevalence and incidence of bothersome cognitive problems, as measured by the PD-Patient Report of Problems (PD-PROP).</div></div><div><h3>Methods</h3><div>22,760 participants in Fox Insight (FI), an online, longitudinal study, completed Physical Activity Scale of the Elderly (PASE) and PD-PROP, a patient-reported outcome measure through which people with PD (PwP) report their 5 most bothersome problems related to PD. Associations between PASE and reports of cognitive problems (classified using a combination of human curation, natural language processing, and machine learning) were evaluated cross-sectionally. 9114 participants with follow-up PD-PROP assessments and no reported cognitive problems at baseline were included in longitudinal analyses to determine if physical activity levels at baseline are associated with incident reporting of cognitive problems.</div></div><div><h3>Results</h3><div>At baseline, 32% reported at least one cognitive problem and had lower PASE Leisure scores compared with participants who did not report cognitive problems. Lower levels of physical activity were associated with increased odds of reporting cognitive problems, particularly in categories of memory (OR = 0.913), language/word finding (OR = 0.923), and cognitive impairment not otherwise specified (OR = 0.880). Longitudinally, lower baseline self-reported physical activity levels were associated with incident reporting of cognitive problems, particularly memory impairment.</div></div><div><h3>Conclusions</h3><div>Self-reported physical activity levels are modestly associated with both increased prevalence and incident bothersome cognitive problems on the PD-PROP. Due to the subjective nature of these data, results are hypothesis-generating and should not be interpreted as evidence that physical activity prevents cognitive decline.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100504"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149282783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic analysis of adult neuronal ceroid lipofuscinosis caused by CLN6 gene mutation: a case report.","authors":"Yubo Hu, Haochen Sun, Qin Jiang, Juan Wang, Shugang Zhang, Xingjian Lin","doi":"10.1016/j.prdoa.2025.100384","DOIUrl":"10.1016/j.prdoa.2025.100384","url":null,"abstract":"<p><p>Neuronal ceroid lipofuscinosis is a rare lysosomal storage disorder that is difficult to distinguish from other diseases with similar clinical symptoms in its early stages. This article analyzes and summarizes the diagnostic process of a family affected by adult neuronal ceroid lipofuscinosis caused by CLN6 gene mutation. We collected clinical data from a 48-year-old female patient with neuronal ceroid lipofuscinosis who visited Nanjing Brain Hospital in March 2024. She has presented with corresponding symptoms since 2020. The patient underwent whole exome sequencing (WES) and other examinations. WES showed that both the patient and her elder brother, who exhibited similar symptoms of walking instability, were homozygous for a mutation in the CLN6 gene. This variant (c.856C > T: p.Leu286Phe) has not been previously reported and is classified as a Variant of Uncertain Significance (VUS) based on current American College of Medical Genetics and Genomics/Association for Molecular Pathology(ACMG/AMP) guidelines. Both of the patient's parents displayed normal phenotypes but were found to have heterozygous mutations in the CLN6 gene. Additionally, no nuclear inclusion bodies were found in the patient's skin tissue.</p>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"13 ","pages":"100384"},"PeriodicalIF":1.8,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144875574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the needle: how clinician expertise affects outcomes in the treatment of hemifacial spasm.","authors":"Melissa Luque-Llano, Maria Angelica-Coronel, Yulexy T Alvarado-Vanegas, Floralinda García Puello, Laura Arzuza Ortega, Gustavo B Vincos","doi":"10.1016/j.prdoa.2025.100383","DOIUrl":"10.1016/j.prdoa.2025.100383","url":null,"abstract":"<p><strong>Background: </strong>Hemifacial spasm (HFS) is characterized by abnormal contraction of the muscles innervated by the seventh cranial nerve. It is usually benign and diagnosed clinically. The effectiveness of botulinum toxin (BoNT) for its treatment has been well demonstrated. However, adverse events (AEs) resulting from its administration remain a concern, and some patients express reluctance to be treated by resident physicians, even when under expert supervision.</p><p><strong>Objective: </strong>To determine the association between the level of expertise of the neurology professional and the presence of AEs following BoNT administration in patients with HFS.</p><p><strong>Methods: </strong>A cross-sectional descriptive study with an analytical phase conducted at Hospital Occidente de Kennedy (Bogotá, Colombia). Out of 88 medical records reviewed, 73 met all inclusion criteria. Data analysis was performed using SPSS software version 22.</p><p><strong>Results: </strong>A predominance of female patients was observed, accounting for 74 % of the study population. The mean age of symptom onset was 54.5 ± 12.7 years, with a median symptom duration of 9 years. In most cases, the left side was affected (53.4 %). The average number of botulinum toxin applications per patient was 2.6 during the study period. Adverse events occurred in 12.6 % of cases, primarily mild facial paresis (7.9 %), hematoma (2.6 %), and eyelid ptosis (2.1 %).</p><p><strong>Conclusions: </strong>The results did not show a statistically significant association between the level of expertise and the occurrence of adverse events. The frequency of observed adverse events was similar between the groups. This suggests that the occurrence of adverse events following BoNT administration was comparable regardless of whether the procedure was performed by a neurologist or a resident under supervision.</p>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"13 ","pages":"100383"},"PeriodicalIF":1.8,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144875573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of pregabalin and gabapentin on essential tremor: a systematic review and meta-analysis.","authors":"Hooman Pourbala, Zhale Nahavandi, Arash Maghsoudlou, Melina Gazerani Farahani, Avin Khallaghi, Sepehr Izadi, Mehrdad Faizi, Mehran Ghaffari, Hadi Esmaily","doi":"10.1016/j.prdoa.2025.100381","DOIUrl":"10.1016/j.prdoa.2025.100381","url":null,"abstract":"<p><strong>Introduction: </strong>Essential tremor (ET) is a common neurological disorder characterized by involuntary rhythmic oscillations. Emerging evidence suggests that gabapentinoids, including gabapentin and pregabalin, may be effective in managing ET. This study aimed to assess the efficacy of gabapentinoids in treating ET by analyzing data from randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>A systematic search was conducted across various databases to identify relevant RCTs utilizing gabapentin or pregabalin. Tremor severity was evaluated using the total tremor score (TTS) and accelerometry.</p><p><strong>Results: </strong>In a between-group <i>meta</i>-analysis of seven RCTs (N = 235), gabapentinoids did not significantly outperform placebo in reducing TTS or its subscales. Accelerometry data suggested a non-significant trend favoring gabapentinoids.However, within-group analyses demonstrated a significant reduction in TTS from baseline with gabapentinoids overall (P = 0.016), an effect driven by gabapentin (P = 0.021) but not pregabalin. No significant within-group improvements were observed for TTS subscales or accelerometry measures post-treatment.</p><p><strong>Conclusion: </strong>This <i>meta</i>-analysis found no significant advantage of gabapentinoids over placebo in ET. However, within-group analyses demonstrated that gabapentin-but not pregabalin-significantly reduced tremor severity from baseline, suggesting a potential therapeutic signal that warrants further investigation. Larger, standardized trials are needed to identify which patient subgroups, if any, may benefit from gabapentin therapy.</p>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"13 ","pages":"100381"},"PeriodicalIF":1.8,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144875575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Falls during a remote observational Parkinson's disease study: AT-HOME PD2 initial results","authors":"Peggy Auinger, Alison M. Hoyt, Kenneth A Eaton, R. J. Wilson, Cladd E. Stevens, Mariana Alves Porto, Katrina Schmier, Kasey M. Murphy, Stephanie Benvengo, Mariana H.G. Monje, Eric A. Macklin, Dan Weintraub, Kevin Biglan, Alberto Ascherio, Alberto J. Espay, Caroline M. Tanner, Daniel Novák, James C. Beck, Tanya Simuni, Solveig K. Sieberts, E. Ray Dorsey, Michael A. Schwarzschild, Ruth B. Schneider","doi":"10.1016/j.parkreldis.2025.107560","DOIUrl":"https://doi.org/10.1016/j.parkreldis.2025.107560","url":null,"abstract":"","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"134 1","pages":"107560-107560"},"PeriodicalIF":0.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147914331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital speech assessments and machine learning for differentiation of neurodegenerative diseases","authors":"Kyurim Kang ,&nbsp;Adonay S. Nunes ,&nbsp;Ilkay Yildiz Potter ,&nbsp;Ram Kinker Mishra ,&nbsp;Andrew Geronimo ,&nbsp;Jamie L. Adams ,&nbsp;Catherine Isroff ,&nbsp;Jesse E. Wang ,&nbsp;Ashkan Vaziri ,&nbsp;Anne-Marie Wills ,&nbsp;Alexander Pantelyat","doi":"10.1016/j.prdoa.2025.100389","DOIUrl":"10.1016/j.prdoa.2025.100389","url":null,"abstract":"<div><h3>Introduction</h3><div>Speech impairment is a prevalent symptom of neurological disorders, including Parkinson’s disease (PD), Progressive Supranuclear Palsy (PSP), Huntington’s disease (HD), and Amyotrophic Lateral Sclerosis (ALS), with mechanisms and severity varying across and within conditions. Scalable digital health tools and machine learning (ML) are essential for diagnosing and tracking neurodegenerative disease.</div></div><div><h3>Methods</h3><div>A total of 92 individuals were included in this study (21 PSP, 21 PD, 18 HD, 15 ALS, and 16 healthy elderly controls (CTR)). The Rainbow Passage was collected on a digital device and analyzed to extract 12 speech features representing speech production. A set of Elastic Net ML models was trained on these speech features to differentiate between diagnostic classes. A specialized Support Vector Machine ML model was then developed to differentiate PSP from PD.</div></div><div><h3>Results</h3><div>Elastic Net models achieved a balanced accuracy of 77% over 5 diagnostic classes (group-specific sensitivities of 76% for PSP, 67% for PD, 83% for HD, 73% for ALS, and 88% for CTR) and 83% over 4 diagnostic classes (group-specific sensitivities of 83% for PSP-PD, 83% for HD, 73% for ALS, and 94% for CTR). The PSP vs. PD classification model demonstrated a balanced accuracy of 85%, with sensitivity of 88% for PSP and 82% for PD. Key speech features differentiated clinical conditions, with <em>Total Voiced Time</em> being the strongest positive feature for combined PSP-PD. In HD, ALS, and CTR, <em>Ratio Extra Words, Pauses per Second</em>, and <em>Intelligibility</em> were the most strongly differentiating features, respectively. <em>Articulatory Rate</em> emerged as the most distinguishing feature between PD and PSP.</div></div><div><h3>Conclusion</h3><div>Our findings highlight the potential of digital health technology and ML in identifying and monitoring speech features in neurodegenerative diseases.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"13 ","pages":"Article 100389"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of levodopa and deep brain stimulation on visual impairments in Parkinson’s disease","authors":"Sana Aslam ,&nbsp;Markey Olson ,&nbsp;Melissa Kovacs ,&nbsp;Pireh Ansari ,&nbsp;Amputch Karukote ,&nbsp;Justine Chan ,&nbsp;Shadi Barbu ,&nbsp;Sydney Felsen ,&nbsp;Holly A. Shill ,&nbsp;Charles H. Adler","doi":"10.1016/j.prdoa.2025.100390","DOIUrl":"10.1016/j.prdoa.2025.100390","url":null,"abstract":"<div><h3>Background</h3><div>Parkinson’s disease (PD) often causes visual changes that impair visuospatial processing, reading speed, and contrast acuity, impacting patients’ quality of life.</div></div><div><h3>Objectives</h3><div>This study aimed to investigate the effects of levodopa and deep brain stimulation (DBS) on visual symptoms associated with PD.</div></div><div><h3>Methods</h3><div>Patients were assessed either before DBS surgery (both off and on medication) or at their first DBS programming session (off medication, with and without stimulation). The King-Devick reading speed and color contrast visual tests were administered in each condition, evaluating high and low contrast across black, red, and yellow.</div></div><div><h3>Results</h3><div>Reading speed and color contrast acuity did not change following levodopa dosing or when deep brain stimulation was off or on. However, those patients that had testing before and after DBS showed a non-significant trend towards improvement in their rapid reading test scores from pre-DBS to post-DBS and black color contrast sensitivity using the 2.5% contrast.</div></div><div><h3>Conclusions</h3><div>Although levodopa and DBS did not significantly improve reading speed or contrast acuity after single dosing or turning DBS on and off, in this small study, these findings provide valuable insights into the stability of these visual symptoms under current treatments. There was evidence that DBS surgery may improve certain aspects of reading speed and contrast acuity and further study is needed. This work underscores the need for innovative approaches to enhance visual function in PD.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"13 ","pages":"Article 100390"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145018748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of tremor in people with multiple sclerosis: A systematic review and meta-analysis","authors":"Saeed Vaheb ,&nbsp;Danial Dehghani Firouzabadi ,&nbsp;Hamed Ghoshouni ,&nbsp;Mohammad Yazdan Panah ,&nbsp;Vahid Shaygannejad ,&nbsp;Omid Mirmosayyeb","doi":"10.1016/j.prdoa.2025.100315","DOIUrl":"10.1016/j.prdoa.2025.100315","url":null,"abstract":"<div><h3>Background</h3><div>Multiple sclerosis (MS) is a chronic neurodegenerative disorder causing various symptoms, including tremors, which significantly affect the quality of life and disability in people with MS (PwMS). Previous studies report a wide range of tremor frequency in PwMS, necessitating a comprehensive review for reliable estimates.</div></div><div><h3>Objectives</h3><div>This review aimed to elucidate the frequency rate of tremor among PwMS.</div></div><div><h3>Method</h3><div>A systematic search was conducted in PubMed/MEDLINE, Embase, Scopus, and Web of Science up to April 27, 2024, to identify studies evaluating various types of tremors in PwMS. The Meta-proportion method implemented in R software version 4.0.0, utilizing a random-effects model, was employed to estimate the pooled frequency rates of tremor, with its 95% confidence interval (CI), among PwMS.</div></div><div><h3>Results</h3><div>From 3780 studies, 14 studies encompassing 17,458 PwMS (71.5 % female) were included. The mean age was 46.4 years, with a disease duration of 9.3 years and an Expanded Disability Status Scale (EDSS) score of 3.4. The pooled frequency of tremor was 33.32 % (95 % CI: 23.47 % to 44.88 %; I² = 98 %; <em>p</em>-heterogeneity &lt; 0.01). Subgroup analysis by sample size revealed that the pooled frequency of tremor in PwMS was significantly lower (<em>p</em>-value &lt; 0.01) in studies with over 200 participants (22.46, 95 % CI: 15.69 % to 31.08 %, I² = 99 %; <em>p</em>-heterogeneity &lt; 0.01) compared to those with fewer than 200 participants (47.65, 95 % CI: 31.97 % to 63.81 %, I² = 91 %; <em>p</em>-heterogeneity &lt; 0.01)</div></div><div><h3>Conclusion</h3><div>Tremor is a prevalent complaint in PwMS. These findings highlight the necessity for targeted supportive, therapeutic, and rehabilitative interventions to effectively address this prevalent issue in PwMS.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"12 ","pages":"Article 100315"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143679783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}